Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study
Main finding · Urolithiasis (new onset urinary stone)Result — go to the resultHazard ratio 0.64 95% CI 0.51–0.80Authors' conclusion
This population-based cohort study found that allopurinol compared with benzbromarone was associated with a substantially lower risk of urolithiasis particularly in the presence of the high cardiovascular risk.
Study context
- Population
- Gout patients initiating first-line ULT, Korea National Health Insurance Service database 2011–20 (mean age 59 years, 79% male)PS-matched 5:1
- Participants
- 61,300 vs 12,260
- Exposure
- Allopurinol vs benzbromarone as first-line ULT
- Allopurinoln = 61,300
- Benzbromaronen = 12,260reference
- Outcome
- New onset urinary stone
Methodological details5:1 propensity-score matched on >80 variables, Cox proportional hazard models
- 5:1 propensity-score matched on >80 variables
- Cox proportional hazard models
Main finding
Urolithiasis (new onset urinary stone) · mean follow-up 322 days
Hazard ratio
0.64
95% CI 0.51–0.80
By group
Allopurinolvs Benzbromarone
HR 0.64 (95% CI 0.51–0.80)
As reported in the abstract
- Urolithiasis cases
- 619
Observational data: associations, not effects.
Secondary outcomes
Urinary stone requiring intervention (secondary outcome)
- ≈44% of urinary stones required intervention
- PS-matched 5:1
Urolithiasis by cardiovascular risk (subgroup)
- Lower risk with allopurinol vs benzbromarone persisted across subgroups but was greater in high than non-high cardiovascular risk subgroup
- P for interaction = 0.02
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study. Rheumatology (Oxford). Published 11 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →